MX350170B - Composición inmunogénica estable de antígenos de staphylococcus aureus. - Google Patents
Composición inmunogénica estable de antígenos de staphylococcus aureus.Info
- Publication number
- MX350170B MX350170B MX2013006960A MX2013006960A MX350170B MX 350170 B MX350170 B MX 350170B MX 2013006960 A MX2013006960 A MX 2013006960A MX 2013006960 A MX2013006960 A MX 2013006960A MX 350170 B MX350170 B MX 350170B
- Authority
- MX
- Mexico
- Prior art keywords
- staphylococcus aureus
- immunogenic compositions
- aureus antigens
- stable immunogenic
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
Abstract
La presente invención se refiere a una composición inmunogénica multi-antígeno o multicomponente liofilizada o reconstituida que comprende al menos un antígeno aislado a partir de una bacteria de estafilococo, y métodos para fabricar la misma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426476P | 2010-12-22 | 2010-12-22 | |
PCT/IB2011/055883 WO2012085872A2 (en) | 2010-12-22 | 2011-12-21 | Stable immunogenic compositions of staphylococcus aureus antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013006960A MX2013006960A (es) | 2013-07-15 |
MX350170B true MX350170B (es) | 2017-08-28 |
Family
ID=45444677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006960A MX350170B (es) | 2010-12-22 | 2011-12-21 | Composición inmunogénica estable de antígenos de staphylococcus aureus. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20130259896A1 (es) |
EP (2) | EP2654784B1 (es) |
JP (1) | JP6097478B2 (es) |
KR (2) | KR101808398B1 (es) |
CN (1) | CN103826656B (es) |
AU (1) | AU2011346535B2 (es) |
BR (1) | BR112013016153A2 (es) |
CA (1) | CA2819120C (es) |
DK (2) | DK2654784T3 (es) |
ES (2) | ES2769425T3 (es) |
HK (1) | HK1197370A1 (es) |
HU (2) | HUE033072T2 (es) |
IL (1) | IL226793B (es) |
MX (1) | MX350170B (es) |
PL (2) | PL2654784T3 (es) |
PT (2) | PT3150222T (es) |
RU (1) | RU2570730C2 (es) |
SI (2) | SI3150222T1 (es) |
WO (1) | WO2012085872A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ553776A (en) | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
EP3461496B1 (en) | 2009-06-22 | 2023-08-23 | Wyeth LLC | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
JP5395264B2 (ja) | 2009-06-22 | 2014-01-22 | ワイス・エルエルシー | 黄色ブドウ球菌(staphylococcusaureus)抗原の免疫原性組成物 |
EP3170508B1 (en) * | 2010-06-04 | 2019-11-13 | Wyeth LLC | Vaccine formulations |
CA2830415A1 (en) * | 2011-03-16 | 2012-12-13 | Regents Of The University Of Minnesota | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
GB201310008D0 (en) * | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
WO2015082571A1 (en) * | 2013-12-04 | 2015-06-11 | Glycovaxyn Ag | Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli |
KR102411781B1 (ko) * | 2013-12-31 | 2022-06-22 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 단일 바이알 백신 제형 |
DK3129001T3 (da) * | 2014-04-10 | 2020-01-20 | Asit Biotech S A | Hsp-fri fremstilling af allergen |
JP2020531421A (ja) * | 2017-08-16 | 2020-11-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 肺炎球菌コンジュゲートワクチン製剤 |
GB201802339D0 (en) | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
KR102649069B1 (ko) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물 |
JP7079984B2 (ja) | 2018-07-28 | 2022-06-03 | エクソコバイオ インコーポレイテッド | エキソソームの凍結乾燥方法 |
KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
CN115666639A (zh) * | 2020-01-13 | 2023-01-31 | 阿帕特夫研究和发展有限公司 | 用于防止治疗性蛋白吸附到药物递送系统部件的方法和组合物 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
BE1008978A5 (fr) | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
EP0857214A1 (en) | 1995-10-16 | 1998-08-12 | Smithkline Beecham Plc | Novel saliva binding protein |
GB9622159D0 (en) | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6680195B1 (en) | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
WO1999027109A2 (en) | 1997-11-26 | 1999-06-03 | Inhibitex, Inc. | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS) |
WO2000012131A1 (en) * | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
SK287689B6 (sk) | 2000-06-08 | 2011-06-06 | Intercell Ag | Použitie molekuly oligodeoxynukleovej kyseliny na výrobu imunostimulačnej farmaceutickej kompozície a farmaceutický prípravok |
AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
WO2002098369A2 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
ATE451386T1 (de) | 2001-06-07 | 2009-12-15 | Wyeth Corp | Mutantenformen von cholera holotoxin als adjuvans |
JP4424984B2 (ja) | 2001-06-15 | 2010-03-03 | インヒビテックス インコーポレーテッド | コアグラーゼ陰性ブドウ球菌および黄色ブドウ球菌由来の表面蛋白質を認識する、交差反応性モノクローナルおよびポリクローナル抗体 |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
US20060251675A1 (en) | 2003-03-17 | 2006-11-09 | Michael Hagen | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
NZ553776A (en) * | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
EP1998802A2 (en) * | 2006-03-30 | 2008-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
GB0606416D0 (en) * | 2006-03-30 | 2006-05-10 | Glaxosmithkline Biolog Sa | Immunogenic composition |
AR060188A1 (es) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
US20070253985A1 (en) | 2006-04-26 | 2007-11-01 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
RU2541784C2 (ru) * | 2006-11-07 | 2015-02-20 | Санофи Пастер Байолоджикс Ко. | Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения |
MX2010008799A (es) | 2008-03-05 | 2010-09-07 | Sanofi Pasteur | Proceso para estabilizar una composicion de vacuna que contiene adyuvante. |
JP5395264B2 (ja) * | 2009-06-22 | 2014-01-22 | ワイス・エルエルシー | 黄色ブドウ球菌(staphylococcusaureus)抗原の免疫原性組成物 |
-
2011
- 2011-12-21 ES ES16193095T patent/ES2769425T3/es active Active
- 2011-12-21 ES ES11804822.2T patent/ES2614815T3/es active Active
- 2011-12-21 EP EP11804822.2A patent/EP2654784B1/en active Active
- 2011-12-21 PT PT161930953T patent/PT3150222T/pt unknown
- 2011-12-21 KR KR1020157031951A patent/KR101808398B1/ko active IP Right Grant
- 2011-12-21 HU HUE11804822A patent/HUE033072T2/hu unknown
- 2011-12-21 SI SI201131825T patent/SI3150222T1/sl unknown
- 2011-12-21 PL PL11804822T patent/PL2654784T3/pl unknown
- 2011-12-21 HU HUE16193095A patent/HUE047263T2/hu unknown
- 2011-12-21 CA CA2819120A patent/CA2819120C/en active Active
- 2011-12-21 PL PL16193095T patent/PL3150222T3/pl unknown
- 2011-12-21 US US13/993,887 patent/US20130259896A1/en not_active Abandoned
- 2011-12-21 CN CN201180068105.5A patent/CN103826656B/zh active Active
- 2011-12-21 RU RU2013128277/15A patent/RU2570730C2/ru active IP Right Revival
- 2011-12-21 PT PT118048222T patent/PT2654784T/pt unknown
- 2011-12-21 EP EP16193095.3A patent/EP3150222B1/en active Active
- 2011-12-21 AU AU2011346535A patent/AU2011346535B2/en not_active Ceased
- 2011-12-21 DK DK11804822.2T patent/DK2654784T3/en active
- 2011-12-21 SI SI201131064A patent/SI2654784T1/sl unknown
- 2011-12-21 KR KR1020137018851A patent/KR20130114210A/ko active Application Filing
- 2011-12-21 DK DK16193095.3T patent/DK3150222T3/da active
- 2011-12-21 BR BR112013016153A patent/BR112013016153A2/pt not_active Application Discontinuation
- 2011-12-21 WO PCT/IB2011/055883 patent/WO2012085872A2/en active Application Filing
- 2011-12-21 MX MX2013006960A patent/MX350170B/es active IP Right Grant
- 2011-12-22 JP JP2011280781A patent/JP6097478B2/ja active Active
-
2013
- 2013-06-06 IL IL226793A patent/IL226793B/en active IP Right Grant
-
2014
- 2014-10-30 HK HK14110911.9A patent/HK1197370A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX350170B (es) | Composición inmunogénica estable de antígenos de staphylococcus aureus. | |
ZA201903620B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof | |
AU2018243910A8 (en) | A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof | |
EP3470526A3 (en) | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use | |
EP4286000A3 (en) | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof | |
NZ595689A (en) | Compositions for immunising against staphylococcus aureus | |
NZ597154A (en) | Immunogenic compositions of staphylococcus aureus antigens | |
MX357202B (es) | Composicion de particula tipo virus. | |
PL1954308T3 (pl) | Stabilizatory do liofilizowanych szczepionek | |
AU2013331781A8 (en) | Immunogenic composition comprising 1 or more Streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising Protein E and/or PilA from Haemophilus influenzae. | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX349948B (es) | Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae. | |
TW200716670A (en) | Use of panton-valentine leukocidin for treating and preventing staphylococcus infections | |
NZ741342A (en) | Daptomycin formulations and uses thereof | |
IL276661A (en) | Immunogenic preparation containing staphylococcal antigens | |
ZA201900070B (en) | Antibodies with low immunogenicity and uses thereof | |
JOP20190038B1 (ar) | تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته | |
MX2011012248A (es) | Anticuerpos o sus fragmentos dirigidos contra un epitope de staphylococcus aureus de isaa o isab. | |
WO2012031260A3 (en) | Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof | |
GB2568440A (en) | Modified factor H binding protein | |
MX2018011016A (es) | Formulaciones estables para liofilizar particulas terapeuticas. | |
GB201114923D0 (en) | Immunogenic proteins and compositions | |
NZ626296A (en) | Compositions and methods for antibodies targeting factor p | |
GB2515669A (en) | Bacterial vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |